|
WO2004099388A2
(en)
|
2003-03-05 |
2004-11-18 |
Proteologics, Inc. |
Cbl-b polypeptides, complexes and related methods
|
|
EP1960551A2
(en)
|
2005-12-01 |
2008-08-27 |
Medical Prognosis Institute |
Methods and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy
|
|
DK2069381T3
(da)
|
2006-09-13 |
2016-03-14 |
Univ Columbia |
Midler og fremgangsmåder til udløsning af anti-tumorimmunrespons
|
|
AT506041A1
(de)
|
2007-12-10 |
2009-05-15 |
Univ Innsbruck |
Verfahren zur erhöhung der immunreaktivität
|
|
DK2242749T3
(da)
|
2008-02-05 |
2013-06-17 |
Hoffmann La Roche |
Nye pyridinoner og pyridazinoner
|
|
JP2012529535A
(ja)
|
2009-06-12 |
2012-11-22 |
ブリストル−マイヤーズ スクイブ カンパニー |
キナーゼモジュレーターとして有用なニコチンアミド化合物
|
|
KR101862327B1
(ko)
|
2010-05-07 |
2018-05-29 |
질레드 코네티컷 인코포레이티드 |
피리돈 및 아자-피리돈 화합물 및 사용 방법
|
|
AR082590A1
(es)
|
2010-08-12 |
2012-12-19 |
Hoffmann La Roche |
Inhibidores de la tirosina-quinasa de bruton
|
|
EP2471548A1
(de)
|
2010-12-28 |
2012-07-04 |
Apeiron Biologics AG |
siRNA gegen Cbl-b und optional IL2 und IL12 zur Verwendung in der Behandlung von Krebs
|
|
UA111756C2
(uk)
|
2011-11-03 |
2016-06-10 |
Ф. Хоффманн-Ля Рош Аг |
Сполуки гетероарилпіридону та азапіридону як інгібітори тирозинкінази брутона
|
|
US8669251B2
(en)
|
2011-11-03 |
2014-03-11 |
Genentech, Inc. |
8-fluorophthalazin-1(2H)-one compounds
|
|
JP2015508414A
(ja)
|
2012-01-12 |
2015-03-19 |
イエール ユニバーシティ |
Ｅ３ユビキチンリガーゼによる標的タンパク質および他のポリペプチドの分解増強のための化合物および方法
|
|
CA2881761A1
(en)
|
2012-09-13 |
2014-03-20 |
Christine E. Brotherton-Pleiss |
Inhibitors of bruton's tyrosine kinase
|
|
US10308707B2
(en)
|
2013-12-02 |
2019-06-04 |
Aaron Diamond Aids Research Center |
Bispecific HIV-1-neutralizing antibodies
|
|
EP3077388A1
(en)
|
2013-12-05 |
2016-10-12 |
Pharmacyclics, LLC |
Inhibitors of bruton's tyrosine kinase
|
|
GB201506871D0
(en)
|
2015-04-22 |
2015-06-03 |
Glaxosmithkline Ip Dev Ltd |
Novel compounds
|
|
MA42623A
(fr)
|
2015-06-02 |
2018-06-20 |
Pharmacyclics Llc |
Inhibiteurs de la tyrosine kinase de bruton
|
|
CN108026088B
(zh)
|
2015-07-17 |
2021-02-12 |
武田药品工业株式会社 |
用作hdac抑制剂的噁二唑衍生物
|
|
PL3532607T3
(pl)
|
2016-10-26 |
2024-07-01 |
Iovance Biotherapeutics, Inc. |
Restymulacja kriokonserwowanych limfocytów naciekających guza nowotworowego
|
|
TWI788307B
(zh)
|
2016-10-31 |
2023-01-01 |
美商艾歐凡斯生物治療公司 |
用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞
|
|
AU2017363252B2
(en)
|
2016-11-22 |
2021-08-19 |
Dana-Farber Cancer Institute, Inc. |
Degradation of Bruton's tyrosine kinase (BTK) by conjugation of BTK inhibitors with E3 ligase ligand and methods of use
|
|
AU2017370694A1
(en)
|
2016-12-08 |
2019-07-25 |
Icahn School Of Medicine At Mount Sinai |
Compositions and methods for treating CDK4/6-mediated cancer
|
|
JOP20190224A1
(ar)
|
2017-03-29 |
2019-09-26 |
Iovance Biotherapeutics Inc |
عمليات من أجل إنتاج الخلايا اللمفاوية المرتشحة للأورام واستخداماتها في العلاج المناعي
|
|
EP3743063A4
(en)
|
2018-01-26 |
2021-10-20 |
Nurix Therapeutics, Inc. |
CBL-B INHIBITORS AND THEIR METHODS OF USE
|
|
JP2021512059A
(ja)
|
2018-01-29 |
2021-05-13 |
ダナ−ファーバー キャンサー インスティテュート，インコーポレイテッド |
ブルトン型チロシンキナーゼ（ｂｔｋ）阻害剤のｅ３リガーゼリガンドとのコンジュゲーションによるｂｔｋの分解および使用方法
|
|
TW202513579A
(zh)
*
|
2018-06-19 |
2025-04-01 |
美商百歐恩泰美國公司 |
新抗原及其用途
|
|
CN113412259B
(zh)
*
|
2018-10-15 |
2024-07-16 |
紐力克斯治疗公司 |
通过泛素蛋白酶体途径降解btk的双官能化合物
|
|
WO2020167518A1
(en)
|
2019-02-13 |
2020-08-20 |
Nurix Therapeutics, Inc. |
Bifunctional compounds for degrading btk via ubiquitin proteosome pathway
|
|
AU2020272937B2
(en)
|
2019-04-09 |
2024-09-26 |
Nurix Therapeutics, Inc. |
3-substituted piperidine compounds for Cbl-b inhibition, and use of a Cbl-b inhibitor in combination with a cancer vaccine and/or oncolytic virus
|
|
JP7587528B2
(ja)
|
2019-05-17 |
2024-11-20 |
ニューリックス セラピューティクス，インコーポレイテッド |
Ｃｂｌ－ｂ阻害のためのシアノシクロブチル化合物及びその使用
|
|
CA3144450A1
(en)
|
2019-06-26 |
2020-12-30 |
Nurix Therapeutics, Inc. |
Substituted benzyl-triazole compounds for cbl-b inhibition, and further uses thereof
|
|
AU2020320195A1
(en)
|
2019-07-30 |
2022-03-10 |
Nurix Therapeutics, Inc. |
Urea, amide, and substituted heteroaryl compounds for Cbl-b inhibition
|
|
US12121540B2
(en)
|
2019-09-24 |
2024-10-22 |
Nurix Therapeutics, Inc. |
CBL inhibitors and compositions for use in adoptive cell therapy
|
|
WO2021091575A1
(en)
|
2019-11-08 |
2021-05-14 |
Nurix Therapeutics, Inc. |
Bifunctional compounds for degrading btk via ubiquitin proteosome pathway
|
|
MX2022006672A
(es)
*
|
2019-12-04 |
2022-08-08 |
Nurix Therapeutics Inc |
Compuestos bifuncionales para la degradacion de btk a traves de la via de proteosomas de ubiquitina.
|
|
AU2022310182A1
(en)
|
2021-07-14 |
2024-02-01 |
Nurix Therapeutics, Inc. |
Bifunctional compounds for degrading btk with diminished imid activity
|
|
EP4373493A1
(en)
*
|
2021-07-23 |
2024-05-29 |
Nurix Therapeutics, Inc. |
Bifunctional compounds for degrading btk with enhanced imid activity
|
|
WO2023076303A1
(en)
|
2021-10-26 |
2023-05-04 |
Nurix Therapeutics, Inc. |
Piperidinylpyrazine-carboxamide compounds for treating and preventing cancer and for degrading btk
|